202 related articles for article (PubMed ID: 17069937)
1. Population-based seroprevalence of Neisseria meningitidis serogroup C capsular antibody before the introduction of conjugate vaccine, in Australia.
Backhouse JL; Gidding HF; MacIntyre CR; McIntyre PB; Gilbert GL
Vaccine; 2007 Jan; 25(7):1310-5. PubMed ID: 17069937
[TBL] [Abstract][Full Text] [Related]
2. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
3. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
[TBL] [Abstract][Full Text] [Related]
4. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario.
Gasparini R; Rizzetto R; Sasso T; Rizzitelli E; Manfredi P; Risso D; Gentile C; Ciofi degli Atti M; Panatto D
Vaccine; 2009 May; 27(25-26):3435-8. PubMed ID: 19200821
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera.
Guirola M; Carmenate T; Menéndez T; Alvarez A; González S; Guillén G
J Microbiol Methods; 2006 Apr; 65(1):135-43. PubMed ID: 16122825
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.
Trotter C; Findlow J; Balmer P; Holland A; Barchha R; Hamer N; Andrews N; Miller E; Borrow R
Clin Vaccine Immunol; 2007 Jul; 14(7):863-8. PubMed ID: 17494636
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
11. Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.
Harris SL; Tsao H; Ashton L; Goldblatt D; Fernsten P
Clin Vaccine Immunol; 2007 Apr; 14(4):397-403. PubMed ID: 17287312
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
13. [Comparison on the levels of human serum antibody against Neisseria meningitidis serogroup C measured using serum bactericidal assay and ELISA].
Zhu BQ; Xu L; Zhou HJ; Shao ZJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 May; 33(5):521-4. PubMed ID: 22883183
[TBL] [Abstract][Full Text] [Related]
14. [Study on the bactericidal antibody against Neisseria meningitidis serogroup C strains after immunization with a divalent polysaccharide (A plus C) vaccine].
Xu L; Luo LZ; Zhu BQ; He L; Gao Y; Shao ZJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):619-21. PubMed ID: 19957632
[TBL] [Abstract][Full Text] [Related]
15. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies.
Rezaei N; Aghamohammadi A; Siadat SD; Nejati M; Ahmadi H; Moin M; Pourpak Z; Kamali S; Norouzian D; Tabaraei B; Read RC
Vaccine; 2007 Jul; 25(29):5308-14. PubMed ID: 17574314
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
17. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
18. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
20. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
